Sarepta Therapeutics is led by Dr. Michael Severino, who assumed the role of Chief Executive Officer. Bringing extensive leadership experience across the global biopharmaceutical sector—including serving as CEO of Tessera Therapeutics and as vice chairman and president of AbbVie—he guides the company's overarching corporate strategy and clinical pipeline development. He succeeded long-time chief executive Doug Ingram, focusing on advancing precision genetic medicines for rare neuromuscular and genetic conditions.